Transcript
A (0:01)
Live from NPR News, I'm Lakshmi Singh. The US Supreme Court will now weigh arguments over the future of birthright citizenship today. A majority of justices, including some who President Trump nominated, seem skeptical about the administration's effort to limit the constitutional provision, but NPR's Kerry Johnson reports the outcome remains far from certain.
B (0:25)
President Trump issued an executive order on Day one that would end citizenship to babies born to people who are in the country illegally or here to work or visit on a temporary basis. If the Supreme Court agrees, that order could affect 250,000 babies born in the US each year and potentially be used to help revoke the citizenship of many others born earlier. Trump attended for the solicitor general's arguments, but left as attorney Cecilia Wong made her case for people challenging his order. Wong told the justices to agree with the president would radically rewrite the constitution and upend more than 150 years of settled law, a decision as expected near the end of the Supreme Court term this summer. Carrie Johnson, NPR News.
A (1:09)
President Trump is expected to address the nation about the Iran war tonight at 9 Eastern. The conflict the US and Israel began against the Islamic Republic is in its fifth week. Thousands of U.S. troops are stationed in the region. Trump now says the Iranian regime is relenting, but that appears to be very much in dispute. NPR's Deepa Shivaram has more on social media.
C (1:31)
Trump said Iran's new leader asked the US For a ceasefire. The president said he would consider it if the Strait of Hormuz, a critical route for oil, was opened. Until then, Trump said the US Would continue its attacks on Iran. But Iran's foreign ministry called Trump's comments saying that Iran asked for a ceasefire, quote, false and baseless. Trump has said the war, which has gone on for a month, should end in the next two to three weeks. Deepa Shivaram, NPR News, the White House.
A (1:59)
The Food and Drug Administration approved another obesity pill today, this one from drug maker Eli Lilly. NPR's Sydney Lupkin reports on how this medicine is different.
D (2:10)
Eli Lilly's new pill is called Fundeo, although this is the same company behind Zepbound, the blockbuster injectable obesity medicine. Eli Lilly decided not to take Zepbound's main ingredient and make it in pill form. Instead, the company developed a new ingredient or for Glipron. Daniel Skavronsky, the company's chief scientific and medical officer, says until now, all of these GLP1 drugs have been peptides, meaning they need to be taken as injections or as a pill with restrictions. Make something as simple as possible. That means we had to rely on more complicated science. Lilly hasn't announced a list price yet, but it says people with commercial insurance could pay as little as $25 a month. And for people paying cash, the lowest dose will cost $149 a month. Sidi Lupkin, NPR News.
